Top

European Radiology

Published in:

01-03-2017 | Vascular-Interventional

Risk factors for and causes and treatment of recurrence of inferior vena cava type of Budd-Chiari syndrome after stenting in China: A retrospective analysis of a large cohort

Authors: Wen-Dong Li, Hui-Ying Yu, Ai-Min Qian, Jian-Jie Rong, Ye-Qing Zhang, Xiao-Qiang Li

Published in: European Radiology | Issue 3/2017

Abstract

Objectives

To explore the risk factors for recurrence of inferior vena cava (IVC)-type Budd–Chiari syndrome (BCS) after stenting and evaluate the feasibility and primary outcomes of endovascular therapies for recurrent BCS.

Methods

A retrospective analysis of 219 patients was performed to identify risk factors for recurrence. The images of the recurrent patients during follow-up duration and interventional surgery were also reviewed to find the possible reasons of recurrence. The outcome of endovascular therapies for recurrent BCS was evaluated by Kaplan–Meier analysis.

Results

Among the 219 patients, 172 patients with primary IVC-type BCS underwent stenting and 28 patients experienced recurrence. Multivariate analysis identified age, Child–Pugh score, MELD and total bilirubin as independent recurrent indicators. Possible causes of recurrence include thrombosis in the stent, re-obstruction in or above the stent, and stent-related hepatic vein obstruction. Twenty-five patients with recurrent BCS underwent endovascular therapies with a few complications and achieved a high level of short- and mid-term patency.

Conclusion

Age, total bilirubin and severity of liver function are the main risk factors for BCS recurrence. These risks might contribute to thrombosis or subsequent fibrous obstruction. Endovascular therapies are effective and safe management options that yield positive outcomes for recurrent BCS.

Key Points

• Risk factors for recurrent Budd–Chiari syndrome were identified by multivariate analysis.

• Causes of recurrent Budd–Chiari syndrome were investigated by assessing radiological images.

• There is a correlation between risk factors and causes of recurrence.

• Endovascular therapies for recurrent Budd–Chiari syndrome are effective and safe.

Valla DC (2009) Primary Budd-Chiari syndrome. J Hepatol 50:195–203CrossRefPubMed

Menon KV, Shah V, Kamath PS (2004) The Budd-Chiari syndrome. N Engl J Med 350:578–585CrossRefPubMed

Horton JD, San Miguel FL, Membreno F et al (2008) Budd-Chiari syndrome: illustrated review of current management. Liver Int Off J Int Assoc Stud Liver 28:455–466CrossRef

Janssen HL, Garcia-Pagan JC, Elias E et al (2003) Budd-Chiari syndrome: a review by an expert panel. J Hepatol 38:364–371CrossRefPubMed

Han G, Qi X, Zhang W et al (2013) Percutaneous recanalization for Budd-Chiari syndrome: an 11-year retrospective study on patency and survival in 177 Chinese patients from a single center. Radiology 266:657–667CrossRefPubMed

Klein AS (2006) Management of Budd-Chiari syndrome. Liver Transplant Off Publ Am Assoc Stud Liver Dis Int Liver Transplant Soc 12:S23–S28

Kage M, Arakawa M, Kojiro M, Okuda K (1992) Histopathology of membranous obstruction of the inferior vena cava in the Budd-Chiari syndrome. Gastroenterology 102:2081–2090CrossRefPubMed

Wu T, Wang L, Xiao Q et al (2002) Percutaneous balloon angioplasty of inferior vena cava in Budd-Chiari syndrome-R1. Int J Cardiol 83:175–178CrossRefPubMed

Yang XL, Cheng TO, Chen CR (1996) Successful treatment by percutaneous balloon angioplasty of Budd-Chiari syndrome caused by membranous obstruction of inferior vena cava: 8-year follow-up study. J Am Coll Cardiol 28:1720–1724CrossRefPubMed

10.

Gillams A, Dick R, Platts A, Irving D, Hobbs K (1991) Dilatation of the inferior vena cava using an expandable metal stent in Budd-Chiari syndrome. J Hepatol 13:149–151CrossRefPubMed

11.

Reza F, Naser DE, Hossein G, Mehrdad Z (2007) Combination of thrombolytic therapy and angioplastic stent insertion in a patient with Budd-Chiari syndrome. World J Gastroenterol WJG 13:3767–3769CrossRefPubMed

12.

Zhang CQ, Fu LN, Xu L et al (2003) Long-term effect of stent placement in 115 patients with Budd-Chiari syndrome. World J Gastroenterol WJG 9:2587–2591PubMed

13.

DeLeve LD, Valla DC, Garcia-Tsao G (2009) American Association for the Study Liver D. Vascular disorders of the liver. Hepatology 49:1729–1764CrossRefPubMed

14.

Kamath PS, Wiesner RH, Malinchoc M et al (2001) A model to predict survival in patients with end-stage liver disease. Hepatology 33:464–470CrossRefPubMed

15.

Darwish Murad S, Valla DC, de Groen PC et al (2004) Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. Hepatology 39:500–508CrossRefPubMed

16.

Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R (1973) Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60:646–649CrossRefPubMed

17.

Zeitoun G, Escolano S, Hadengue A et al (1999) Outcome of Budd-Chiari syndrome: a multivariate analysis of factors related to survival including surgical portosystemic shunting. Hepatology 30:84–89CrossRefPubMed

18.

Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC (2000) A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 31:864–871CrossRefPubMed

19.

Tang TJ, Batts KP, de Groen PC et al (2001) The prognostic value of histology in the assessment of patients with Budd-Chiari syndrome. J Hepatol 35:338–343CrossRefPubMed

20.

Tripathi D, Macnicholas R, Kothari C et al (2014) Good clinical outcomes following transjugular intrahepatic portosystemic stent-shunts in Budd-Chiari syndrome. Aliment Pharmacol Ther 39:864–872CrossRefPubMed

21.

Gao X, Gui E, Lu Z et al (2015) Risk factors of recurrence among 471 Chinese patients with Budd-Chiari syndrome. Clin Res Hepatol Gastroenterol 39:620–626CrossRefPubMed

22.

Dabbagh O, Oza A, Prakash S, Sunna R, Saettele TM (2010) Coagulopathy does not protect against venous thromboembolism in hospitalized patients with chronic liver disease. Chest 137:1145–1149CrossRefPubMed

23.

Tripodi A, Primignani M, Chantarangkul V et al (2009) An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. Gastroenterology 137:2105–2111CrossRefPubMed

24.

Tripodi A, Anstee QM, Sogaard KK, Primignani M, Valla DC (2011) Hypercoagulability in cirrhosis: causes and consequences. J Thromb Haemost JTH 9:1713–1723CrossRefPubMed

25.

Wu H, Nguyen GC (2010) Liver cirrhosis is associated with venous thromboembolism among hospitalized patients in a nationwide US study. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 8:800–805

26.

Ng KJ, Lee YK, Huang MY, Hsu CY, Su YC (2015) Risks of venous thromboembolism in patients with liver cirrhosis: a nationwide cohort study in Taiwan. J Thromb Haemost JTH 13:206–213CrossRefPubMed

27.

Tripodi A, Primignani M, Lemma L, Chantarangkul V, Mannucci PM (2013) Evidence that low protein C contributes to the procoagulant imbalance in cirrhosis. J Hepatol 59:265–270CrossRefPubMed

28.

Northup PG, Sundaram V, Fallon MB et al (2008) Hypercoagulation and thrombophilia in liver disease. J Thromb Haemost JTH 6:2–9PubMed

29.

Mancuso A (2014) Budd-chiari syndrome management: timing of treatment is an open issue. Hepatology 59:1213CrossRefPubMed

30.

Seijo S, Plessier A, Hoekstra J et al (2013) Good long-term outcome of Budd-Chiari syndrome with a step-wise management. Hepatology 57:1962–1968CrossRefPubMed

31.

Fisher NC, McCafferty I, Dolapci M et al (1999) Managing Budd-Chiari syndrome: a retrospective review of percutaneous hepatic vein angioplasty and surgical shunting. Gut 44:568–574CrossRefPubMedPubMedCentral

32.

Darwish Murad S, Plessier A, Hernandez-Guerra M et al (2009) Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med 151:167–175CrossRefPubMed

33.

Qi X, De Stefano V, Wang J et al (2013) Prevalence of inherited antithrombin, protein C, and protein S deficiencies in portal vein system thrombosis and Budd-Chiari syndrome: a systematic review and meta-analysis of observational studies. J Gastroenterol Hepatol 28:432–442CrossRefPubMed

Title: Risk factors for and causes and treatment of recurrence of inferior vena cava type of Budd-Chiari syndrome after stenting in China: A retrospective analysis of a large cohort
Authors: Wen-Dong Li
Hui-Ying Yu
Ai-Min Qian
Jian-Jie Rong
Ye-Qing Zhang
Xiao-Qiang Li
Publication date: 01-03-2017
Publisher: Springer Berlin Heidelberg
Published in: European Radiology / Issue 3/2017
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-016-4482-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Risk factors for and causes and treatment of recurrence of inferior vena cava type of Budd-Chiari syndrome after stenting in China: A retrospective analysis of a large cohort

Abstract

Objectives

Methods

Results

Conclusion

Key Points

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusion

Key Points

Please log in to get access to this content

Other articles of this Issue 3/2017

Diagnostic performance of susceptibility-weighted magnetic resonance imaging for the assessment of sub-coracoacromial spurs causing subacromial impingement syndrome

Erratum to: Aiming for a shorter rheumatoid arthritis MRI protocol: can contrast-enhanced MRI replace T2 for the detection of bone marrow oedema?

Diagnostic value of MRS-quantified brain tissue lactate level in identifying children with mitochondrial disorders

Low contrast detectability and spatial resolution with model-based Iterative reconstructions of MDCT images: a phantom and cadaveric study

Prediction of infarction development after endovascular stroke therapy with dual-energy computed tomography

Fluoroscopic removal of retrievable self-expandable metal stents in patients with malignant oesophageal strictures: Experience with a non-endoscopic removal system